Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Rijeka | OTHER |
Not provided
Not provided
Not provided
Not provided
This pilot study aims to evaluate the safety and efficacy of PMA-zeolite when used in patients with uncontrolled CD (Crohn´s disease). The effect of the PMA-zeolite will be compared between a control-group (healthy volunteers) receiving either PMA-zeolite or placebo and the test-group (suffering from uncontrolled CD) and receiving either PMA-zeolite or placebo. In addition, this pilot-study should furthermore provide indications for the effect-size in order to estimate an effect for an eventual further human trial.
Background of the study Crohn´s disease (CD) is a chronic progressive destructive disease. Approximately one-fifth of adult and paediatric patients already have evidence of a structuring or penetrating intestinal complications at diagnosis. Despite decades of research, the aetiology of CD remains unknown. Disease treatments include a variety of approaches like dietary changes and immunosuppressive anti-TNFa antibodies as well as ancillary antibiotic therapy. Another interesting and promising approach in this context might be the supplementation of the certified medical device PMA-(Panaceo micro activation)-zeolite (a specific natural zeolite-clinoptilolite) due to its properties documented through many studies. In particular, the promising clinical results from a randomized controlled trial (RCT) with PMA-zeolite need to be highlighted. The strengthening/ supporting of the intestinal wall integrity in healthy subjects suffering from intestinal problems was measured in this RCT and is claimed as intended main action of the PMA-zeolite. Based on these results the application of PMA-zeolite is an interesting and promising approach in patients with uncontrolled CD.
Hypothesis In the present trial, it is being tested if supplementing PMA-zeolite can lead to an improvement of the defined markers and parameters (reduction of local and systemic inflammation, changes of the microbiota in the gut, positive detoxifying effect and general improvement of quality of life) in patients with uncontrolled CD compared to a healthy test-group.
Aims This pilot study aims to evaluate the safety and efficacy of PMA-zeolite when used in patients with uncontrolled CD. The effect of the PMA-zeolite will be compared between a control-group (healthy volunteers) receiving either PMA-zeolite or placebo and the test-group (suffering from uncontrolled CD) and receiving either PMA-zeolite or placebo. In addition, this pilot-study should furthermore provide indications for the effect-size in order to estimate an effect for an eventual further human trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group + cellulose (Group A) | Placebo Comparator | healthy subjects (control group) receive placebo (cellulose) as powder |
|
| Control group + PMA-zeolite(Group B) | Active Comparator | healthy subjects (control group) receive PMA-zeolite as powder |
|
| UCD-group + Cellulose (Group C) | Placebo Comparator | subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder |
|
| UCD-group + PMA-zeolite (Group D) | Active Comparator | subjects with uncontrolled Crohn disease receive PMA-zeolite as powder |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cellulose | Device | The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Zonulin concentration in stool (ng/ml) | As the intestinal wall permeability is linked to several conditions, such as the Crohn Disease it is hypothesized that a change of Zonulin (biomarker for permeability of intestinal wall) is detectable with/without supplementation of the study-substance. Measurement: stool stool sample (by ELISA kit) Standard Value for Zonulin: < 55 ng/ml . | 0(baseline) and after 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Bacterial diversity in the marbus crohn patients | bactieria of assessment: Lactobacillus, Escherichia, bifidobacteria Measurement: stool sample (16S RNA sequencing on stool sampling) | 0(baseline) and after 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of blood parameters | Blood samples for measurement of definied parameters:
|
Inclusion Criteria:
Healthy volunteers (at least 18 years old) for first two groups (A,B), homogenous starting group in age (30-60Y) and sex (m/f )
o The health-status will be confirmed through anamnesis.
Groups C and D will include patients with confirmed Crohn's disease that are treated with standard therapy and despite of treatment do not achieve the appropriate disease remission. Patients with the intermediate type of disease will be also included in groups C and D.
Signed informed consent as per usual recommendations in vigour in the Republic of Slovenia.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Krešimir Pavelić, Phd, M.D. | Contact | + 385 98 247164 | pavelic@unipu.hr | |
| Sandra Kraljević Pavelić, Phd | Contact | 51 584569 | + 385 | sandrakp@uniri.hr |
| Name | Affiliation | Role |
|---|---|---|
| Krešimir Pavelić, PhD, M.D. | Juraj Dobrila University of Pula | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Clinical Centre Ljubljana | Recruiting | Ljubljana | 1000 | Slovenia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35712111 | Derived | Kraljevic Pavelic S, Saftic Martinovic L, Simovic Medica J, Zuvic M, Perdija Z, Krpan D, Eisenwagen S, Orct T, Pavelic K. Clinical Evaluation of a Defined Zeolite-Clinoptilolite Supplementation Effect on the Selected Blood Parameters of Patients. Front Med (Lausanne). 2022 May 27;9:851782. doi: 10.3389/fmed.2022.851782. eCollection 2022. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
The pilot-study is a randomized, placebo-controlled and double blinded study. The 4 subject-groups are consisting of group A and B with healthy subjects (A and B are divided into a placebo-group and into a PMA-zeolite- group) and group C and D which are subjects suffering from CD (C and D are divided into a placebo-group and into a PMA-zeolite- group). No washout phase is planned, but if food-supplements are taken this will be protocolled. The diagnostics will be performed through the defined parameters at defined time-points.
Not provided
Not provided
Not provided
| PMA-zeolite | Device | The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks. |
|
| 0(baseline) and after 12 weeks |
| Rate of Safety and tolerability | Rate of tolerability and safety levels of minerals and metals | 0(baseline) and after 12 weeks |
| Medical Thermal Centre Fontana | Recruiting | Maribor | 2000 | Slovenia |
|
| Slovenj Gradec General Hospital | Recruiting | Slovenj Gradec | 2380 | Slovenia |
|
| D007410 | Intestinal Diseases |